logo
Plus   Neg
Share
Email

Vertex: EU Approves SYMKEVI With KALYDECO For 6-11 Years Children With Cystic Fibrosis

Vertex Pharmaceuticals Incorporated (VRTX) announced Friday that the European Commission has granted approval of the label extension for SYMKEVI (tezacaftor/ivacaftor) with KALYDECO (ivacaftor) for eligible children with Cystic Fibrosis or CF ages 6-11 years.

CF is a rare, life-shortening genetic disease that affects the lungs, liver, GI tract, sinuses, sweat glands, pancreas and reproductive tract. CF is caused by a defective and/or missing CFTR protein resulting from certain mutations in the CFTR gene.

The approval is for the treatment of CF in patients ages 6 years and older who have two copies of the F508del mutation in the cystic fibrosis transmembrane conductance regulator or CFTR gene or one copy of the F508del mutation and one copy of one of 14 mutations in the CFTR gene that result in residual CFTR activity.

SYMKEVI with KALYDECO will be immediately available to additional eligible patients in Germany and will be available shortly in countries that have entered into innovative long-term reimbursement agreements with Vertex, including the UK, Denmark and the Republic of Ireland.

In all other countries, Vertex will work closely with relevant authorities in Europe to secure access for eligible patients.

In Europe, SYMKEVI with KALYDECO is already approved for the treatment of people with CF ages 12 years and older who have either two copies of the F508del mutation in the CFTR gene, or one copy of the F508del mutation and a copy of one of the 14 mutations in which the CFTR gene results in residual CFTR protein activity.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
General Electric Co. filed a lawsuit against Siemens Energy AG, accusing the German power distribution company of stealing trade secrets for gas turbines. Siemens Energy allegedly used the information to get at least nine contracts to supply gas turbines to public utilities, and also covered up improper business gains. Following a court ruling, the U.S. Food and Drug Administration postponed the effective date for tobacco manufacturing companies to display new health warnings on cigarette packets and in advertisements, by additional 90 days. The warnings with color images is to promote greater public understanding of the negative health consequences of smoking. JPMorgan Chase & Co (JPM) reported strong results in the fourth quarter of 2020, with net profit up 42% largely driven by credit reserve releases of $2.9 billion. The Group said it ended the year with a CET1 ratio of 13.1% and capital above $200 billion, providing with meaningful capacity to further...
Follow RTT